Lorcaserin and metabolic disease: weight‐loss dependent and independent effects

OBJECTIVE: Weight management pharmacotherapies can improve metabolic diseases through weight‐dependent and weight‐independent effects. Lorcaserin is a selective 5‐hydroxytryptamine 2C receptor agonist. The objective of this analysis is to quantify the relative contribution of weight loss to the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Bays, H., Perdomo, C., Nikonova, E., Knoth, R., Malhotra, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298312/
https://www.ncbi.nlm.nih.gov/pubmed/30574343
http://dx.doi.org/10.1002/osp4.296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298312/
https://www.ncbi.nlm.nih.gov/pubmed/30574343
http://dx.doi.org/10.1002/osp4.296

Ejemplares similares